The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma. Feasibility and efficacy of ...

Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC). This is an ...

Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...

Pfizer and Astellas Pharma have shared positive results from a late-stage study of their antibody-drug conjugate Padcev (enfortumab vedotin-ejfv ... with Merck’s PD-1 inhibitor Keytruda (pembrolizumab ...

Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] Technology appraisal guidance Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant ...